IMTX
Immatics Nv
NASDAQ · Biotechnology
$9.63
+1.06 (+12.37%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 195.63M | 118.68M | 326.37M | 330.72M | 310.79M |
| Net Income | 19.10M | 10.43M | -48,914,216 | -35,950,365 | -46,474,411 |
| EPS | — | — | — | — | — |
| Profit Margin | 9.8% | 9.3% | -15.0% | -10.9% | -15.0% |
| Rev Growth | +64.8% | +64.8% | -5.3% | -2.7% | -3.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 17.70M | 17.70M | 413.10M | 416.60M | 451.59M |
| Total Equity | 627.81M | 627.81M | 676.65M | 804.78M | 720.44M |
| D/E Ratio | 0.03 | 0.03 | 0.61 | 0.52 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -37,417,215 | -21,565,463 | -62,378,752 | -62,958,224 | -63,441,351 |
| Free Cash Flow | — | — | -30,588,227 | -53,039,983 | -41,589,145 |